tiprankstipranks
Trending News
More News >
TransMedics Group Inc (TMDX)
NASDAQ:TMDX
US Market

TransMedics Group (TMDX) Stock Statistics & Valuation Metrics

Compare
1,370 Followers

Total Valuation

TransMedics Group has a market cap or net worth of $3.05B. The enterprise value is $2.38B.
Market Cap$3.05B
Enterprise Value$2.38B

Share Statistics

TransMedics Group has 33,824,223 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding33,824,223
Owned by Insiders3.59%
Owned by Institutions0.59%

Financial Efficiency

TransMedics Group’s return on equity (ROE) is 0.16 and return on invested capital (ROIC) is 4.98%.
Return on Equity (ROE)0.16
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)4.98%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee606.51K
Profits Per Employee0.00
Employee Count728
Asset Turnover0.55
Inventory Turnover3.85

Valuation Ratios

The current PE Ratio of TransMedics Group is 58.42. TransMedics Group’s PEG ratio is -0.24.
PE Ratio58.42
PS Ratio0.00
PB Ratio9.06
Price to Fair Value9.06
Price to FCF42.45
Price to Operating Cash Flow42.45
PEG Ratio-0.24

Income Statement

In the last 12 months, TransMedics Group had revenue of 441.54M and earned 35.46M in profits. Earnings per share was 1.07.
Revenue441.54M
Gross Profit262.08M
Operating Income37.50M
Pretax Income35.78M
Net Income35.46M
EBITDA69.95M
Earnings Per Share (EPS)1.07

Cash Flow

In the last 12 months, operating cash flow was 48.80M and capital expenditures -129.74M, giving a free cash flow of -80.94M billion.
Operating Cash Flow48.80M
Free Cash Flow-80.94M
Free Cash Flow per Share-2.39

Dividends & Yields

TransMedics Group pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.52
52-Week Price Change-21.76%
50-Day Moving Average75.32
200-Day Moving Average101.77
Relative Strength Index (RSI)67.19
Average Volume (3m)1.07M

Important Dates

TransMedics Group upcoming earnings date is May 8, 2025, TBA Not Confirmed.
Last Earnings DateFeb 27, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date

Financial Position

TransMedics Group as a current ratio of 8.30, with Debt / Equity ratio of 200.75%
Current Ratio8.30
Quick Ratio7.52
Debt to Market Cap0.22
Net Debt to EBITDA1.75
Interest Coverage Ratio2.60

Taxes

In the past 12 months, TransMedics Group has paid 316.00K in taxes.
Income Tax316.00K
Effective Tax Rate<0.01

Enterprise Valuation

TransMedics Group EV to EBITDA ratio is 31.37, with an EV/FCF ratio of 44.96.
EV to Sales4.97
EV to EBITDA31.37
EV to Free Cash Flow44.96
EV to Operating Cash Flow44.96

Balance Sheet

TransMedics Group has $336.65M in cash and marketable securities with $8.65M in debt, giving a net cash position of $122.27M billion.
Cash & Marketable Securities$336.65M
Total Debt$8.65M
Net Cash$122.27M
Net Cash Per Share$3.61
Tangible Book Value Per Share$6.47

Margins

Gross margin is 59.31%, with operating margin of 8.49%, and net profit margin of 8.03%.
Gross Margin59.31%
Operating Margin8.49%
Pretax Margin8.10%
Net Profit Margin8.03%
EBITDA Margin15.84%
EBIT Margin11.37%

Analyst Forecast

The average price target for TransMedics Group is $102.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$102.50
Price Target Upside11.40% Upside
Analyst ConsensusModerate Buy
Analyst Count8
Revenue Growth Forecast82.74%
EPS Growth Forecast

Scores

Smart Score1
AI Score78
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis